Cognition Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| EBITDA | (6.0m) | (13.4m) | (21.1m) | (25.5m) | - | - | - |
| Profit | (7.8m) | (11.7m) | (21.4m) | (25.8m) | (37.0m) | (47.4m) | (86.3m) |
| EV / EBITDA | - | -10.4x | -2.9x | -2.3x | - | - | - |
| R&D budget | 12.9m | 18.6m | 30.3m | 37.2m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - |
| N/A | - |
| N/A | $2.5m | Grant | |
| N/A | $6.6m | Grant | |
$16.6m | Grant | ||
$3.3m | Grant | ||
| N/A | N/A | Series B | |
| N/A | $1.6m | Grant | |
| N/A | $45.2m | IPO | |
* | N/A | Grant | |
* | $2.1m | Grant | |
* | N/A | $11.5m | Post IPO Equity |
| Total Funding | AUD116m | ||
Related Content
Recent News about Cognition Therapeutics
EditCognition Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company operates in the healthcare and biotechnology market, primarily targeting conditions such as Alzheimer's disease, dementia with Lewy bodies, and age-related macular degeneration. Cognition Therapeutics' core business model revolves around the discovery and development of small molecule drugs that modulate cellular damage response mechanisms. Their lead candidate, CT1812, is currently undergoing clinical trials and aims to displace toxic protein oligomers on neurons, thereby restoring normal cellular function. The company generates revenue through research grants, partnerships, and potential future sales of their therapeutic compounds. Cognition Therapeutics serves a global market, including patients, healthcare providers, and research institutions.
Keywords: neurodegenerative diseases, Alzheimer's, dementia, cellular mechanisms, biopharmaceutical, CT1812, clinical trials, small molecule drugs, healthcare, biotechnology.